Navigation Links
Atacama Labs Enters Into Partnership With Excella Gmbh, Which is Part of Fareva Holding, a Top 10 Global Contract Manufacturer
Date:3/4/2010

HELSINKI, Finland, March 4, 2010 /PRNewswire/ --

- A Finnish Company ATACAMA LABS OY and a German Based EXCELLA GmbH (Fareva Holding SA) Have Signed a Contract Manufacturing Agreement to Jointly Market and Sell PDG Granule and Tablet Manufacturing Services for the Pharmaceutical Industry

- Excella / Atacama Labs Offer for the Pharmaceutical Industry

Atacama Labs Oy has developed an innovative oral drug delivery technology (called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology is aimed to replace existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and will help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.

The Excella / Atacama Labs partnership offers a cGMP compliant and FDA / EMEA / Anvisa certified environment to house Atacama's innovative and fully automated PDG equipment.

"We can develop almost any API (including difficult ones) into higher drug load tablets with good hardness and dissolution profiles and our clients can profit from new tablet characteristics to extend the life cycle of expiring drugs, which can mean several more years of protected sales of a blockbuster drug. In both cases, global economics can be hundreds of millions of additional revenue, naturally subject to magnitude of drug revenue," Mr. Mittwich, CEO of the Atacama Labs Oy concludes.

Fareva Holding SA : Manufacturing excellence

Excella GmbH is part of FAREVA Holding, one of the top 10 contract manufacturing organizations in the world. Fareva today is covering services in four fields - Pharmaceuticals, Cosmetics, Home Care & Industrial and Food.

FAREVA's Pharma Division provides a full service, ranging from pharmaceutical and chemical development, pilot scale manufacturing, supply of clinical studies till industrial-scale production, packaging and quality control. Ten pharmaceutical sites located throughout Europe serve the customer's needs for practically all marketed dosage forms as well as APIs.

Excella GmbH - located in Nuremberg, Germany - provides Contract Manufacturing Services, especially for the development, clinical supply and commercial manufacturing of solid dosage forms specially for cytotoxics, high potent or other critical actives with low occupational exposure levels.

"Atacama Lab's Pneumatic Dry Granulation or PDG Technology(TM) is revolutionary in the sense that it offers significant advantages in terms of API treatability, development speed and costs over today's dry and wet granulation processes " Dr. Michael Tschope , General Manager Pharma, Excella GmbH.

About Atacama Labs Oy

Atacama Labs Oy is a privately owned specialty pharmaceutical company that offers

    - galenic development from test granulations to full galenic development,
      and
    - contract manufacturing services from tablets to fully packaged
      products.


    The Company is located in Helsinki, Finland.
    http://www.atacamalabs.com

SOURCE Atacama Labs Oy

Back to top
'/>"/>
SOURCE Atacama Labs Oy
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Fibrocell Science, Inc. Enters Into Financing Agreement
2. US Fermenters Market to Reach $180 million by 2015, According to New Report by Global Industry Analysts, Inc.
3. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
4. The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close
5. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
6. MRI & X-Ray Outsourcing Increasing From Hospitals and Imaging Centers Worldwide
7. iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets
8. China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS
9. Childrens Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
10. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
11. Dr M Group Selects Health Robotics Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Phoenix, AZ (PRWEB) , ... May 25, 2016 ... ... Arizona, Dr. Michael Fitzmaurice recently became double board-certified in surgery and surgery of ... 31, 2015. Dr. Fitzmaurice is no stranger to going above and beyond in ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) ... of wound healing and tissue regeneration. , The novel method, developed by WPI ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, global image ... Cybernetics corporate branding reflects a results-driven revitalization for a company with a renewed ... components include a crisp, refreshed logo and a new web presence. , “I ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):